Keros Therapeutics, Inc.
KROSNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $219.78M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $9.69$22.55
- Volume (live)
- -
- Avg. volume (3M)
- 184.60K
Keros Therapeutics (KROS) Stock Price & Financial Analysis
Keros Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $10.63 - $11.13 |
|---|---|
| 52-Week High | $22.55 |
| 52-Week Low | $9.69 |
| Open | $11.11 |
| Volume (last close) | 169.64K |
| Average Volume (3M) | 184.60K |
| Revenue (TTM) | 15.01M |
|---|---|
| Net Income (TTM) | -83.16M |
| Free Cash Flow (TTM) | -48.49M |
| EPS (TTM) | −$3.10 |
| Profit Margin | -553.88% |
| Operating Margin | -675.82% |
| Return on Equity (ROE) | -31.70% |
| Debt to Equity | 0.06 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 219.78M |
|---|---|
| Shares Outstanding | 19.80M |
| Price to Sales (P/S) | 14.64 |
| Price to Book (P/B) | 0.84 |
| EV/EBITDA | 0.23 |
| 50-Day MA | $11.14 |
|---|---|
| 200-Day MA | $12.54 |
| 1-Year Change | −19.74% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Keros Therapeutics at a Glance
As of the Oct 16, 2026 close, Keros Therapeutics (KROS) has a market capitalization of $219.78M. The stock trades at 14.6× sales. Over the trailing twelve months it lost $83.16M on revenue of $15.01M and burned $48.49M of free cash flow. Revenue fell 93.5% year over year.
As of its latest reported balance sheet, it holds $257.61M in cash and securities against $15.72M of debt, a net cash position of $241.88M.
Keros Therapeutics does not currently pay a dividend.
The share price is down 19.7% over the past year. At $10.66 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $9.69 to $22.55, below its 200-day moving average of $12.54.
Based on 9 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $18.80, 76.4% above the Oct 16, 2026 close.
Frequently Asked Questions About Keros Therapeutics
What is the current stock price for KROS?
As of the Oct 16, 2026 close, KROS stock trades at $10.66. The 52-week range is $9.69–$22.55, with a day range of $10.63–$11.13.
What is the P/E ratio for KROS?
The P/E ratio (Price-to-Earnings) for KROS is shown in the Key Statistics section. This valuation metric helps compare Keros Therapeutics, Inc. to industry peers.
Does KROS pay dividends?
Keros Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for KROS?
Based on ratings from 9 professional analysts over the last 90 days, the consensus for KROS is Hold. The average 12-month price target is $18.80, a 76.4% upside from the Oct 16, 2026 close of $10.66.
What is the market cap of KROS?
As of the Oct 16, 2026 close, Keros Therapeutics's market capitalization is $211.1M, classifying it as a micro-cap company. Keros Therapeutics operates in the Healthcare sector within the Biotechnology industry.